Connect Sign In
COVID-19 IgG, Qualitative by CIA
Ordering Recommendation
Use for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2 (COVID-19) that develop in response to natural infection with SARS-CoV-2. These antibodies do not develop as a result of a COVID-19 vaccination. There are no current recommendations for assessing COVID-19 vaccine response.
New York DOH Approval Status
Specimen Required
Serum separator tube (SST) or EDTA plasma
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 0.5mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.25 mL)
Refrigerated
Grossly hemolyzed, grossly icteric, or severely lipemic specimens. Postmortem specimens.
Preferred: ARUP Standard Transport Tube for specimen submission (ARUP Item# 15824).
Refrigerated: 1 week; Frozen: 1 month
Methodology
Qualitative Chemiluminescent Immunoassay (CLIA)
Performed
Mon, Wed, Fri
Reported
1-5 days
Reference Interval
Negative
Interpretive Data
The COVID-19 IgG, Qualitative by CIA test is for in vitro diagnostic use under an FDA Emergency Use Authorization (EUA). In compliance with this authorization, please visit https://www.aruplab.com/infectious-disease/coronavirus/testing for more information and to access the applicable information sheets. This test should not be used for screening of donated blood.
Use for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2 (COVID-19) that develop in response to natural infection with SARS-CoV-2. These antibodies do not develop as a result of a COVID-19 vaccination. There are no current recommendations for assessing COVID-19 vaccine response.
Emergency Use Authorization (EUA)
Note
Hotline History
CPT Codes
86769
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3002777 | COVID-19 IgG, Qualitative | 94563-4 |
Aliases
- 2019-nCoV
- Coronavirus Disease - 2019
- COVID-19 Illness
- COVID-2019
- COVID19 IgG Ab
- SARS-CoV-2
